Paper39028129
Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.
Zhang K and 6 others. World J Mens Health, 2025. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review. Papers, record 39028129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39028129
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35123819 | Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. | Eur Urol | 2022 | https://conductscience.org/library/papers/35123819 | PubMed |
| 2 | 33782057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
| 3 | 35789204 | The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. | Nat Rev Urol | 2022 | https://conductscience.org/library/papers/35789204 | PubMed |
| 4 | 31725935 | Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. | BJU Int | 2020 | https://conductscience.org/library/papers/31725935 | PubMed |
| 5 | 25179590 | Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. | Prostate Cancer Prostatic Dis | 2014 | https://conductscience.org/library/papers/25179590 | PubMed |
| 6 | 31103721 | Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. | Eur Urol Oncol | 2020 | https://conductscience.org/library/papers/31103721 | PubMed |
| 7 | 27697580 | Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. | J Urol | 2017 | https://conductscience.org/library/papers/27697580 | PubMed |
| 8 | 30768957 | Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome. | Magn Reson Imaging | 2019 | https://conductscience.org/library/papers/30768957 | PubMed |
| 9 | 36441776 | A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. | J Urol | 2023 | https://conductscience.org/library/papers/36441776 | PubMed |
| 10 | 30638633 | Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. | Eur Urol | 2019 | https://conductscience.org/library/papers/30638633 | PubMed |
| 11 | 30385049 | Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. | Eur Urol | 2019 | https://conductscience.org/library/papers/30385049 | PubMed |
| 12 | 28796935 | Focal irreversible electroporation as primary treatment for localized prostate cancer. | BJU Int | 2018 | https://conductscience.org/library/papers/28796935 | PubMed |
| 13 | 30211680 | Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. | Diagn Interv Radiol | 2018 | https://conductscience.org/library/papers/30211680 | PubMed |
| 14 | 36073928 | Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years. | J Urol | 2023 | https://conductscience.org/library/papers/36073928 | PubMed |
| 15 | 32488359 | Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). | World J Urol | 2021 | https://conductscience.org/library/papers/32488359 | PubMed |
| 16 | 30986263 | Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. | PLoS One | 2019 | https://conductscience.org/library/papers/30986263 | PubMed |
| 17 | 32209449 | Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. | Lancet | 2020 | https://conductscience.org/library/papers/32209449 | PubMed |
| 18 | 26296371 | The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. | World J Urol | 2016 | https://conductscience.org/library/papers/26296371 | PubMed |
| 19 | 35793110 | Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial. | JAMA Surg | 2022 | https://conductscience.org/library/papers/35793110 | PubMed |
| 20 | 36910902 | Irreversible electroporation for prostate cancer using PSMA PET-CT. | Prostate Int | 2023 | https://conductscience.org/library/papers/36910902 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42755971 | Functional outcomes and biochemical control after radical prostatectomy versus irreversible electroporation for localized prostate cancer. | iScience | 2026 | https://conductscience.org/library/papers/42755971 | PubMed |
| 42614700 | Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications. | Biomater Res | 2026 | https://conductscience.org/library/papers/42614700 | PubMed |
| 42382550 | Irreversible electroporation in focal therapy for prostate cancer: current status and future directions. | Prostate Int | 2026 | https://conductscience.org/library/papers/42382550 | PubMed |
| 42192883 | Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42192883 | PubMed |
| 42099853 | Magnetic resonance imaging/ultrasound fusion-guided targeted biopsy and ultrasound-guided systematic biopsy for prior negative prostate biopsy: A meta-analysis. | Indian J Urol | 2026 | https://conductscience.org/library/papers/42099853 | PubMed |
| 40647385 | Oncological and Functional Outcomes of Hemi-Ablation Versus Focal Ablation for Localized Prostate Cancer Using Irreversible Electroporation. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40647385 | PubMed |
| 40385365 | Extraprostatic Needle Canal Recurrence of Localized Prostate Cancer After Nanoknife Electroporation Ablation Diagnosed with PSMA PET/MRI. | Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/40385365 | PubMed |
| 40117314 | Active matter as the underpinning agency for extraordinary sensitivity of biological membranes to electric fields. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40117314 | PubMed |
| 39623055 | Salvage irreversible electroporation for locally recurrent prostate cancer after definitive radiotherapy: a systematic review. | Prostate Cancer Prostatic Dis | 2025 | https://conductscience.org/library/papers/39623055 | PubMed |
| 39589586 | Advances in irreversible electroporation for prostate cancer. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39589586 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39028129
GET https://conductscience.org/api/papers/v1/39028129/references?page=2